KLRS
Price
$1.99
Change
-$0.03 (-1.49%)
Updated
Oct 22 closing price
Capitalization
47.37M
20 days until earnings call
Intraday BUY SELL Signals
PTHS
Price
$19.79
Change
+$1.09 (+5.83%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
71.59M
21 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

KLRS vs PTHS

KLRS vs PTHS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
KLRS vs. PTHS commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KLRS is a Hold and PTHS is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for KLRS with price predictions
Oct 22, 2026

KLRS in -3.86% downward trend, falling for three consecutive days on October 22, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where KLRS declined for three days, in 312 of 343 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Aroon Indicator for KLRS entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

KLRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.821) is normal, around the industry mean (2.973). P/E Ratio (-1.050) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. KLRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KLRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for PTHS with price predictions
Oct 22, 2026

PTHS's Stochastic Oscillator remains in oversold zone for 15 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PTHS's RSI Indicator exited the oversold zone, 9 of 12 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.

The Moving Average Convergence Divergence (MACD) for PTHS just turned positive on October 13, 2026. Looking at past instances where PTHS's MACD turned positive, the stock continued to rise in 20 of 25 cases over the following month. The odds of a continued upward trend are 80%.

Following a +1.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where PTHS advanced for three days, in 105 of 132 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

PTHS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PTHS as a result. In 44 of 48 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PTHS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for PTHS entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: PTHS's P/B Ratio (-47.696) is slightly lower than the industry average of (2.973). P/E Ratio (-0.653) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (1.470) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. PTHS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PTHS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
KLRS: Fundamental Ratings
KLRS
OUTLOOK RATING
1..100
51
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
93
P/E GROWTH RATING
1..100
8
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
KLRSPTHS
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
75%
Stochastic
ODDS (%)
N/A
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
N/A
Bullish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 3 days ago
80%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 15 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (KLRS: $2.02 vs. PTHS: $18.70)
Brand notoriety: KLRS and PTHS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KLRS: 127% vs. PTHS: 219%
Market capitalization -- KLRS: $47.37M vs. PTHS: $71.59M
KLRS [@Biotechnology] is valued at $47.37M. PTHS’s [@Biotechnology] market capitalization is $71.59M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KLRS’s FA Score shows that 1 FA rating(s) are green while PTHS’s FA Score has 2 green FA rating(s).

  • KLRS’s FA Score: 1 green, 4 red.
  • PTHS’s FA Score: 2 green, 3 red.
According to our system of comparison, both KLRS and PTHS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KLRS’s TA Score shows that 2 TA indicator(s) are bullish while PTHS’s TA Score has 5 bullish TA indicator(s).

  • KLRS’s TA Score: 2 bullish, 2 bearish.
  • PTHS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, PTHS is a better buy in the short-term than KLRS.

Price Growth

KLRS (@Biotechnology) experienced а -5.16% price change this week, while PTHS (@Biotechnology) price change was -7.65% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

KLRS is expected to report earnings on Nov 11, 2026.

PTHS is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
KLRS
Daily Signal:
Gain/Loss:
PTHS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

KLRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KLRS has been loosely correlated with PTHS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if KLRS jumps, then PTHS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KLRS
1D Price
Change %
KLRS100%
-1.49%
PTHS - KLRS
43%
Loosely correlated
+4.76%
RCKT - KLRS
30%
Poorly correlated
+5.00%
ARVN - KLRS
29%
Poorly correlated
+2.18%
CGEN - KLRS
29%
Poorly correlated
-7.55%
MESO - KLRS
28%
Poorly correlated
-2.18%
More

PTHS and

Correlation & Price change

A.I.dvisor indicates that over the last year, PTHS has been loosely correlated with KLRS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if PTHS jumps, then KLRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTHS
1D Price
Change %
PTHS100%
+4.76%
KLRS - PTHS
43%
Loosely correlated
-1.49%
PASG - PTHS
38%
Loosely correlated
-2.23%
INKT - PTHS
36%
Loosely correlated
-5.27%
BGMS - PTHS
33%
Poorly correlated
-5.62%
JSPR - PTHS
27%
Poorly correlated
-1.73%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RLMD3.290.08
+2.49%
Relmada Therapeutics
DOMH1.91-0.01
-0.78%
Dominari Holdings
FJP73.66-1.22
-1.63%
First Trust Japan AlphaDEX Fund (FJP)
ETHB30.66-1.44
-4.49%
iShares Staked Ethereum Trust ETF (ETHB)
ALNT86.18-11.28
-11.57%
Allient